For a self-funded employer, the pharmacy line has quietly become the part of the health plan most likely to break the budget, and nearly all of the pressure now comes from a small group of specialty drugs. These are the high-cost therapies for inflammatory, autoimmune, and complex conditions, and in 2026 they are where plan cost is won or lost. The encouraging news is that the one tool genuinely bending the curve — biosimilars — is finally working at scale. The sobering news is that it is not keeping pace with where the spend is going next.
Start with the trend. The 2026 Artemetrx State of Specialty Spend and Trend report, published by Pharmaceutical Strategies Group, put 2025 specialty drug trend at 10.8% gross and 12.5% net of rebates. Gross specialty cost reached $1,548 per member per year, with the net figure at $1,251. Specialty is no longer a niche line item — it is the dominant driver of pharmacy cost. And the report projects gross specialty cost per member will rise another 32% by 2028. For a plan funding its own claims, that is not an abstraction; it is the number that decides next year’s contribution strategy.
The character of the trend matters as much as the size. The same report found that of the 10.8 points of 2025 trend, 10.6 came from utilization — more people using specialty drugs, and using more of them — while cost per claim added only 0.1. The share of members on at least one specialty drug rose from 4.4% in 2023 to 5.5% in 2025. This is the crucial insight for anyone funding a plan: the driver is not primarily unit price inflation that a sharper rebate deal can offset. It is volume, and volume responds to formulary design, site-of-care management, and clinical oversight, not to price negotiation alone.
Against that backdrop, biosimilars are the genuine success story. Overall biosimilar market share climbed from 22.6% in 2023 to 56.3% in 2025. The Humira biosimilar shift is the headline — biosimilars went from 0.3% of that market in 2023 to 82.4% in 2025, a near-total conversion in two years. Stelara biosimilars captured 18% of their market in their first year, and Stelara’s own utilization fell 29% in 2025 as patients moved. Carriers and benefit advisors broadly credit biosimilar adoption with easing specialty claim costs that would otherwise have risen faster. Where a biosimilar exists and the formulary steers to it, the plan captures real, durable cost reduction.
But the win is partial, and the reason is where the pipeline is heading. Inflammatory-disorder drugs made up eight of the top ten specialty products by spend in 2025, and the fastest-growing among them have no biosimilar competition — utilization of Skyrizi rose 31%, Rinvoq 27%, Dupixent 20%, and Tremfya 16%. As prescribing migrates from older molecules like Humira and Stelara, where biosimilars have driven prices down, toward these newer branded therapies, the cost-reduction lever weakens even as total specialty volume keeps climbing. The biosimilar price advantage is real, but it is being applied to a shrinking share of the problem.
This is precisely the exposure a group-health captive or a well-run self-funded program is built to manage. A fully insured plan simply absorbs this trend as next year’s renewal. A self-funded employer sees the claims data, and a captive gives a group of employers the structure to act on it — pooling specialty risk, setting stop-loss specific and aggregate corridors with specialty trend explicitly modeled rather than assumed, and funding the volatility that a single six-figure claimant can create. The control is not theoretical; it is the difference between reacting to a specialty spike and having already funded for it.
The discipline is in the sequence, and it is the one we bring to every plan. Strategic Discovery examines the plan’s actual specialty claims — who is using what, and where the trend is concentrated. Risk Assessment models the forward trend, including the migration toward therapies with no biosimilar on the horizon, so the budget reflects where spend is going rather than where it has been. Solution Design builds the funding and stop-loss structure around that reality and pairs it with a biosimilar-preferred formulary and clinical management that capture every available price advantage. Ongoing Optimization keeps the strategy current as new biosimilars launch and the pipeline shifts beneath the plan.
Specialty pharmacy is where the modern health plan is decided, and biosimilars have shown that intentional design produces measurable cost reduction. The task for 2026 is to hold that discipline while the spend keeps moving — to capture the biosimilar win where it exists and to fund honestly for the growing share of trend where it does not yet reach. A self-funded plan that sees the whole picture can carry that light forward. A plan that only sees the renewal letter cannot.
Sources used
- Pharmaceutical Strategies Group — 2026 Artemetrx State of Specialty Spend and Trend Report
- PSG — Specialty Drug Utilization Dominant Driver of Trend; Biosimilar Adoption Reshaping the Market (July 2026)
- UnitedHealthcare — How Biosimilars Are Curbing Specialty Drug Costs
- Managed Healthcare Executive — PSG Report: Humira Biosimilars Ease Specialty Drug Claim Costs
- MedBen — Biosimilars Gain Ground Against Rising Specialty Drug Costs
- Covered USA — Biosimilar Switching Guide 2026: Humira, Stelara, Enbrel